Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

Fumihiko Hirai, Makoto Edagawa, Shinichiro Shimamatsu, Ryo Toyozawa, Gouji Toyokawa, Kaname Nosaki, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regard-less of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefitinib remains controversial. The present study therefore retrospectively assessed the efficacy of erlotinib in patients with wild type EGFR who had previously undergone gefitinib therapy. A total of 222 patients with NSCLC who received chemotherapeutic treatment with erlotinib between July 2007 and February 2013 were evaluated. The background variables, response rates, progression-free survival (PFS) and overall survival rates were retrospectively analyzed. The male/female ratio of patients was 103/119, and patients had a median age of 63 years (range, 33-95 years). A total of 10 of the 222 patients had clinical stages IIIB/IV, 191 had adenocarcinoma, 5 had large cell carcinoma, 10 had squamous cell carcinoma and 6 had NSCLC of a variety not otherwise specified. The EGFR mutation was positive, wild type or unknown in 95, 52 and 75 patients, respectively. In the 52 patients with EGFR wild type, there were 3 partial responders, 25 with stable disease and 24 with progressive disease, for a response rate of 6% [95% confidence interval (CI), 1.3-15%]. The median PFS of EGFR wild type and positive were 1.1 months (95% CI, 1.04-1.16 months) and 5.42 months (95% CI, 5.43-5.68 months), respectively. The results of the study demonstrated that erlo-tinib is not sufficiently effective for patients with NSCLC who possess the EGFR wild type status.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalOncology Letters
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Therapeutics
Confidence Intervals
Disease-Free Survival
Erlotinib Hydrochloride
Large Cell Carcinoma
Mutation
Squamous Cell Carcinoma
Adenocarcinoma
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hirai, F., Edagawa, M., Shimamatsu, S., Toyozawa, R., Toyokawa, G., Nosaki, K., ... Ichinose, Y. (2017). Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncology Letters, 14(1), 306-312. https://doi.org/10.3892/ol.2017.6118

Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. / Hirai, Fumihiko; Edagawa, Makoto; Shimamatsu, Shinichiro; Toyozawa, Ryo; Toyokawa, Gouji; Nosaki, Kaname; Yamaguchi, Masafumi; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito.

In: Oncology Letters, Vol. 14, No. 1, 01.01.2017, p. 306-312.

Research output: Contribution to journalArticle

Hirai, F, Edagawa, M, Shimamatsu, S, Toyozawa, R, Toyokawa, G, Nosaki, K, Yamaguchi, M, Seto, T, Takenoyama, M & Ichinose, Y 2017, 'Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type', Oncology Letters, vol. 14, no. 1, pp. 306-312. https://doi.org/10.3892/ol.2017.6118
Hirai, Fumihiko ; Edagawa, Makoto ; Shimamatsu, Shinichiro ; Toyozawa, Ryo ; Toyokawa, Gouji ; Nosaki, Kaname ; Yamaguchi, Masafumi ; Seto, Takashi ; Takenoyama, Mitsuhiro ; Ichinose, Yukito. / Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. In: Oncology Letters. 2017 ; Vol. 14, No. 1. pp. 306-312.
@article{115d0b2384b1401b9f09200ac23872d5,
title = "Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type",
abstract = "Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regard-less of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefitinib remains controversial. The present study therefore retrospectively assessed the efficacy of erlotinib in patients with wild type EGFR who had previously undergone gefitinib therapy. A total of 222 patients with NSCLC who received chemotherapeutic treatment with erlotinib between July 2007 and February 2013 were evaluated. The background variables, response rates, progression-free survival (PFS) and overall survival rates were retrospectively analyzed. The male/female ratio of patients was 103/119, and patients had a median age of 63 years (range, 33-95 years). A total of 10 of the 222 patients had clinical stages IIIB/IV, 191 had adenocarcinoma, 5 had large cell carcinoma, 10 had squamous cell carcinoma and 6 had NSCLC of a variety not otherwise specified. The EGFR mutation was positive, wild type or unknown in 95, 52 and 75 patients, respectively. In the 52 patients with EGFR wild type, there were 3 partial responders, 25 with stable disease and 24 with progressive disease, for a response rate of 6{\%} [95{\%} confidence interval (CI), 1.3-15{\%}]. The median PFS of EGFR wild type and positive were 1.1 months (95{\%} CI, 1.04-1.16 months) and 5.42 months (95{\%} CI, 5.43-5.68 months), respectively. The results of the study demonstrated that erlo-tinib is not sufficiently effective for patients with NSCLC who possess the EGFR wild type status.",
author = "Fumihiko Hirai and Makoto Edagawa and Shinichiro Shimamatsu and Ryo Toyozawa and Gouji Toyokawa and Kaname Nosaki and Masafumi Yamaguchi and Takashi Seto and Mitsuhiro Takenoyama and Yukito Ichinose",
year = "2017",
month = "1",
day = "1",
doi = "10.3892/ol.2017.6118",
language = "English",
volume = "14",
pages = "306--312",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

AU - Hirai, Fumihiko

AU - Edagawa, Makoto

AU - Shimamatsu, Shinichiro

AU - Toyozawa, Ryo

AU - Toyokawa, Gouji

AU - Nosaki, Kaname

AU - Yamaguchi, Masafumi

AU - Seto, Takashi

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regard-less of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefitinib remains controversial. The present study therefore retrospectively assessed the efficacy of erlotinib in patients with wild type EGFR who had previously undergone gefitinib therapy. A total of 222 patients with NSCLC who received chemotherapeutic treatment with erlotinib between July 2007 and February 2013 were evaluated. The background variables, response rates, progression-free survival (PFS) and overall survival rates were retrospectively analyzed. The male/female ratio of patients was 103/119, and patients had a median age of 63 years (range, 33-95 years). A total of 10 of the 222 patients had clinical stages IIIB/IV, 191 had adenocarcinoma, 5 had large cell carcinoma, 10 had squamous cell carcinoma and 6 had NSCLC of a variety not otherwise specified. The EGFR mutation was positive, wild type or unknown in 95, 52 and 75 patients, respectively. In the 52 patients with EGFR wild type, there were 3 partial responders, 25 with stable disease and 24 with progressive disease, for a response rate of 6% [95% confidence interval (CI), 1.3-15%]. The median PFS of EGFR wild type and positive were 1.1 months (95% CI, 1.04-1.16 months) and 5.42 months (95% CI, 5.43-5.68 months), respectively. The results of the study demonstrated that erlo-tinib is not sufficiently effective for patients with NSCLC who possess the EGFR wild type status.

AB - Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regard-less of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefitinib remains controversial. The present study therefore retrospectively assessed the efficacy of erlotinib in patients with wild type EGFR who had previously undergone gefitinib therapy. A total of 222 patients with NSCLC who received chemotherapeutic treatment with erlotinib between July 2007 and February 2013 were evaluated. The background variables, response rates, progression-free survival (PFS) and overall survival rates were retrospectively analyzed. The male/female ratio of patients was 103/119, and patients had a median age of 63 years (range, 33-95 years). A total of 10 of the 222 patients had clinical stages IIIB/IV, 191 had adenocarcinoma, 5 had large cell carcinoma, 10 had squamous cell carcinoma and 6 had NSCLC of a variety not otherwise specified. The EGFR mutation was positive, wild type or unknown in 95, 52 and 75 patients, respectively. In the 52 patients with EGFR wild type, there were 3 partial responders, 25 with stable disease and 24 with progressive disease, for a response rate of 6% [95% confidence interval (CI), 1.3-15%]. The median PFS of EGFR wild type and positive were 1.1 months (95% CI, 1.04-1.16 months) and 5.42 months (95% CI, 5.43-5.68 months), respectively. The results of the study demonstrated that erlo-tinib is not sufficiently effective for patients with NSCLC who possess the EGFR wild type status.

UR - http://www.scopus.com/inward/record.url?scp=85020224165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020224165&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6118

DO - 10.3892/ol.2017.6118

M3 - Article

AN - SCOPUS:85020224165

VL - 14

SP - 306

EP - 312

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -